When was Epicrispr Bio founded?

Epicrispr Bio was founded in 2018.

Where is Epicrispr Bio located?

Epicrispr Bio is located in San Francisco, United States .

Who is the current CEO of Epicrispr Bio?

Amber Salzman is the current CEO of Epicrispr Bio.

How many employees does Epicrispr Bio have?

Epicrispr Bio has 44 employees as of Dec 31, 2022.

Is Epicrispr Bio a funded company?

Epicrispr Bio is a funded company, its first funding round was on Mar 27, 2025.

When was the latest funding round of Epicrispr Bio?

Epicrispr Bio's latest funding round was on Mar 27, 2025.

Where does Epicrispr Bio rank among its competitors?

Epicrispr Bio ranks 101 amongst 891 active competitors.

Who are the top competitors of Epicrispr Bio?

Epicrispr Bio's top competitors are Moderna, BridgeBio and Recursion.

Epicrispr Bio - 2025 Company Profile, Funding & Competitors

Epicrispr Bio is a series B company based in San Francisco (United States), founded in 2018 by . It operates as a Developer of therapeutics for multiple disease. Epicrispr Bio has raised $68M in funding from Ally Bridge Group. The company has 891 active competitors, including 309 funded and 232 that have exited. Its top competitors include companies like Moderna, BridgeBio and Recursion.

Company Details

Developer of therapeutics for multiple diseases. It offers gene therapies using ultracompact Cas proteins which modulate gene expression without cutting DNA. The company's platform leverages the power of CRISPR/Cas9 gene editing to target specific genes and achieve therapeutic outcomes. The pipeline includes EPI-321 for facioscapulohumeral muscular dystrophy, EPI-221, EPI-224 for genetic disorder, EPI 114 and EPI 111 for petinas pigmentosa.

Website
Social
Phone Number: +1

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series B

Total Funding

in 1 round

Latest Funding Round

Investors

Ally Bridge Group & 2 more

Ranked

101^st among

Employee Count

as on Dec 31, 2022

Similar Companies

Moderna &

Legal entities associated with Epicrispr Bio

Epicrispr Bio is associated with 1 legal entity given below:

Legal Entity Name	Date of incorporation	Revenue	Net Profit	Employee Count
	Dec 31, 1999	-	856	388

Epicrispr Bio has raised a total funding of $68M over 1 round. Its latest funding round was a Series B round on Mar 27, 2025 for $68M. 2 investors participated in its latest round, lead by Ally Bridge Group.

Epicrispr Bio has 3 institutional investors including Ally Bridge Group, Solve FSHD and .

Here is the list of recent funding rounds of Epicrispr Bio:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Mar 27, 2025	$68M	Series B	1628904	3801223	Ally Bridge Group, Solve FSHD

Access funding benchmarks and valuations. Sign up today!

View details of Epicrispr Bio's funding rounds and investors

The founders of Epicrispr Bio is . is the CEO of Epicrispr Bio. has founded 1 more company - .

View details of Epicrispr Bio's Founder profiles and Board Members

Epicrispr Bio's employee count trend

Epicrispr Bio has 44 employees as of Dec 22. The total employee count is 300.0% more than what it was in Dec 21. Here is Epicrispr Bio's employee count trend over the years:

Uncover Epicrispr Bio's growth story! Sign up today!

Top competitors of Epicrispr Bio include Moderna, BridgeBio and Recursion. Here is the list of Top 10 competitors of Epicrispr Bio, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	BB Biotech, Gershon Capital听&补尘辫;听	80/100
2nd	BridgeBio 2015, Palo Alto (United States), Acquired	Developer of therapeutics for the treatment of genetic diseases	$434M	Aisling Capital, Athyrium Capital Management听&补尘辫;听	77/100
3rd	Recursion 2013, United States, Public	Developer of AI-enabled drug discovery and development platform	$452M	HTIF, Casdin Capital听&补尘辫;听	77/100
4th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	LanceBio Ventures, Rock Springs Capital听&补尘辫;听	75/100
5th	ATAI 2018, Munich (Germany), Public	Biopharmaceutical company accelerating the development of mental health treatments	$387M	Plus Capital, Daniel Gutenberg听&补尘辫;听	73/100
6th	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	BB Biotech, Ridgeback Capital Management听&补尘辫;听	72/100
7th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Foresite Capital, Perceptive Advisors听&补尘辫;听	72/100
8th	Insitro 2018, San Francisco (United States), Series C	Developer of an AI-enabled technology platform for the treatment of infectious disease	$643M	Foresite Capital, CPP Investments听&补尘辫;听	71/100
9th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	International Biotechnology Trust, Adage Capital Management听&补尘辫;听	69/100
10th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	Aisling Capital, Perceptive Advisors听&补尘辫;听	69/100
101st	Epicrispr Bio 2018, San Francisco (United States), Series B	Developer of therapeutics for multiple disease	$68M	Ally Bridge Group, Solve FSHD听&补尘辫;听	55/100